332 related articles for article (PubMed ID: 11120973)
21. Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures.
Schaumann R; Goldstein EJ; Forberg J; Rodloff AC
J Med Microbiol; 2005 Aug; 54(Pt 8):749-753. PubMed ID: 16014428
[TBL] [Abstract][Full Text] [Related]
22. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Thadepalli H; Reddy U; Chuah SK; Thadepalli F; Malilay C; Polzer RJ; Hanna N; Esfandiari A; Brown P; Gollapudi S
Antimicrob Agents Chemother; 1997 Mar; 41(3):583-6. PubMed ID: 9055997
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Schick DG; Canawati HN; Montgomerie JZ
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
[TBL] [Abstract][Full Text] [Related]
24. Persistence of vancomycin-resistant Enterococcus faecium gastrointestinal tract colonization in antibiotic-treated mice.
Dever LL; Handwerger S
Microb Drug Resist; 1996; 2(4):415-21. PubMed ID: 9158812
[TBL] [Abstract][Full Text] [Related]
25. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
26. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Zhanel GG; Karlowsky JA; Hoban DJ
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
[TBL] [Abstract][Full Text] [Related]
27. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
28. Pharmacodynamics of pulse dosing versus standard dosing: in vitro metronidazole activity against Bacteroides fragilis and Bacteroides thetaiotaomicron.
Ibrahim KH; Gunderson BW; Hermsen ED; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 2004 Nov; 48(11):4195-9. PubMed ID: 15504841
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
30. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
Brook I
Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
[TBL] [Abstract][Full Text] [Related]
31. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
Kronvall G; Holst E
Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
[TBL] [Abstract][Full Text] [Related]
32. Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
Rafay AM
Saudi Med J; 2001 Mar; 22(3):238-43. PubMed ID: 11307110
[TBL] [Abstract][Full Text] [Related]
33. Susceptibility of 497 clinical isolates of gram-negative anaerobes to trovafloxacin and eight other antibiotics.
Rotimi VO; Mokaddas EM; Jamal WY; Khodakhast FB; Verghese TL; Sanyal SC
J Chemother; 1999 Oct; 11(5):349-56. PubMed ID: 10632380
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.
Peterson ML; Hovde LB; Wright DH; Brown GH; Hoang AD; Rotschafer JC
Antimicrob Agents Chemother; 2002 Jan; 46(1):203-10. PubMed ID: 11751135
[TBL] [Abstract][Full Text] [Related]
35. Comparative in vitro activities of clinafloxacin and trovafloxacin against 1,000 isolates of bacteroides fragilis group: effect of the medium on test results.
Snydman DR; Jacobus NV; McDermott LA; Supran SE
Antimicrob Agents Chemother; 2000 Jun; 44(6):1710-2. PubMed ID: 10817736
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.
Tsuji BT; Bulitta JB; Brown T; Forrest A; Kelchlin PA; Holden PN; Peloquin CA; Skerlos L; Hanna D
J Antimicrob Chemother; 2012 Sep; 67(9):2182-90. PubMed ID: 22685161
[TBL] [Abstract][Full Text] [Related]
37. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
38. Killing activities of trovafloxacin alone and in combination with beta-lactam agents, rifampin, or vancomycin against Streptococcus pneumoniae isolates with various susceptibilities to extended-spectrum cephalosporins at concentrations clinically achievable in cerebrospinal fluid.
Fitoussi F; Doit C; Geslin P; Bingen E
Antimicrob Agents Chemother; 1999 Oct; 43(10):2372-5. PubMed ID: 10508009
[TBL] [Abstract][Full Text] [Related]
39. Fluoroquinolone resistance in anaerobic bacteria following exposure to levofloxacin, trovafloxacin, and sparfloxacin in an in vitro pharmacodynamic model.
Ross GH; Wright DH; Hovde LB; Peterson ML; Rotschafer JC
Antimicrob Agents Chemother; 2001 Jul; 45(7):2136-40. PubMed ID: 11408238
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
